prednisone has been researched along with Berger Disease in 91 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the therapeutic effects and safety of a combination therapy of leflunomide (LEF) and prednisone for the treatment of immunoglobulin A (IgA) nephropathy manifesting with nephrotic syndrome." | 9.14 | Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome. ( Li, DM; Liu, XW; Sun, SR; Xu, GS, 2010) |
| "Tacrolimus showed a rapid proteinuria remission in refractory IgAN patients." | 7.78 | Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy. ( Chen, YQ; Liu, LJ; Lv, JC; Shi, SF; Wang, HY; Zhang, H; Zhang, Q; Zhu, L, 2012) |
| "Herein we have described the case of a male renal transplant recipient who developed drug fever apparently related to sirolimus." | 7.75 | Sirolimus-induced drug fever in a renal transplant patient: a case report. ( Aires, I; Carvalho, D; Ferreira, A; Nolasco, F; Pinto, JR; Possante, M; Remédio, F; Santos, JR, 2009) |
| "MMF plus prednisone versus full-dose prednisone did not differ in reducing proteinuria, but patients treated with the former had fewer adverse events in patients with IgAN with active proliferative lesions." | 5.24 | Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial. ( Chen, JH; Chen, N; Fu, P; Hou, JH; Hu, ZX; Le, WB; Liang, SS; Liu, D; Liu, ZH; Liu, ZS; Tian, J; Wang, WM; Zeng, CH; Zhang, HT; Zhou, ML, 2017) |
| " In the multivariate analysis, baseline serum creatinine and 24-h proteinuria were independent predictors of the risk of primary outcome; treatment with prednisone plus ramipril significantly reduced the risk of renal disease progression (hazard ratio 0." | 5.14 | Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. ( Manno, C; Pesce, F; Rossini, M; Schena, FP; Torres, DD, 2009) |
| "To evaluate the therapeutic effects and safety of a combination therapy of leflunomide (LEF) and prednisone for the treatment of immunoglobulin A (IgA) nephropathy manifesting with nephrotic syndrome." | 5.14 | Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome. ( Li, DM; Liu, XW; Sun, SR; Xu, GS, 2010) |
| " Long term alternate-day prednisone treatment according the protocol of Waldo allows to decrease haematuria and proteinuria in children with IgAN and HSN 2." | 5.09 | [Evaluation of prednisone treatment in children with IgA nephropathy and Schönlein-Henoch nephropathy according to the Waldo protocol with regard to pathomorphologic changes in renal biopsy]. ( Mizerska-Wasiak, M; Roszkowska-Blaim, M; Szymanik-Grzelak, H, 2001) |
| "The effects of a combined schedule of prednisone and cyclophosphamide was analysed in the specific subset of IgA nephropathy patients with acute inflammatory histologic changes associated with haematuria and proteinuria." | 5.09 | Steroid and cyclophosphamide in IgA nephropathy. ( Berutti, S; Cesano, G; Ferro, M; Piccoli, G; Roccatello, D; Rossi, D; Salomone, M; Sena, LM, 2000) |
| " For instance, in patients with idiopathic membranous glomerulonephritis a six months treatment with chlorambucil (0." | 5.05 | [Drug treatment of chronic glomerulonephritis: pro]. ( Brodehl, J; Helmchen, U; Koch, KM; Kühn, K, 1985) |
| " Under treatment with oral prednisone mean eGFR significantly improved from 38 ± 21 ml/min to 57 ± 26 ml/min and proteinuria decreased from 981 ± 304 mg/24 hrs to 176 ± 77 mg/24 hrs at the end of follow-up." | 3.81 | Renal sarcoidosis: epidemiological and follow-up data in a cohort of 27 patients. ( Bergner, R; Löffler, C; Löffler, U; Tuleweit, A; Uppenkamp, M; Waldherr, R, 2015) |
| "Tacrolimus showed a rapid proteinuria remission in refractory IgAN patients." | 3.78 | Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy. ( Chen, YQ; Liu, LJ; Lv, JC; Shi, SF; Wang, HY; Zhang, H; Zhang, Q; Zhu, L, 2012) |
| "Herein we have described the case of a male renal transplant recipient who developed drug fever apparently related to sirolimus." | 3.75 | Sirolimus-induced drug fever in a renal transplant patient: a case report. ( Aires, I; Carvalho, D; Ferreira, A; Nolasco, F; Pinto, JR; Possante, M; Remédio, F; Santos, JR, 2009) |
| " Subsequent to cadaveric renal transplant and 8 years of immunosuppressive treatment with prednisone and azathioprine, the patient developed multiple life-threatening infections." | 3.67 | Hypogammaglobulinemia in a renal transplant recipient with antiglomerular basement membrane disease. ( Hasbargen, J; Rickman, W; Smolin, MR, 1988) |
| "The aim of the present study was to evaluate the efficacy of cyclosporine A (CsA) combined with medium/low dose prednisone in the treatment of progressive immunoglobulin A nephropathy (IgAN)." | 2.79 | Cyclosporine A combined with medium/low dose prednisone in progressive IgA nephropathy. ( Guan, GJ; Liu, ZC; Luo, Q; Lv, XA; Xu, L, 2014) |
| "Patients with biopsy-proven immunoglobulin A nephropathy with proteinuria of 1 to 5 g/d of protein." | 2.74 | Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. ( Chen, Y; Jiang, L; Li, G; Lv, J; Singh, AK; Wang, H; Zhang, H, 2009) |
| "IgA nephropathy is virtually known as the most common glomerulopathy to end-stage renal failure in the world." | 2.72 | Efficacy and safety of mycophenolate mofetil in the treatment for IgA nephropathy: a meta-analysis of randomized controlled trials. ( Deng, MH; Fu, R; Huang, YH; Peng, XJ; Tao, SS; Wang, TJ; Zheng, WM; Zhu, C, 2021) |
| "Entry criteria were (1) biopsy-proven IgA nephropathy, (2) estimated GFR > or = 50 ml/min per 1." | 2.72 | Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. ( Cattran, D; Donadio, JV; Fitzgibbons, L; Hirschman, G; Hogg, RJ; Holub, BJ; Hyland, K; Jennette, JC; Julian, BA; Lee, J; Nardelli, N; Sibley, R; Waldo, B; Wyatt, R, 2006) |
| "Group A comprised 12 patients with IgA nephropathy, who had 24-h proteinuria of 0." | 2.71 | Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy. ( Ikeda, M; Kuwajima, H; Okada, M; Sugimoto, K; Takemura, T; Yagi, K; Yanagida, H, 2003) |
| " Ligustrazine with the dosage of 80 mg twice a day was given to 25 patients in the treatment group by intravenous perfusion besides the medicine used in the control group." | 2.71 | [Effect of ligustrazine on proliferative glomerulonephritis]. ( Tang, X, 2003) |
| "IgA nephropathy is progressive in most cases and has no established therapy." | 2.69 | Corticosteroids in IgA nephropathy: a randomised controlled trial. ( Altieri, P; Andrulli, S; Bolasco, PG; Fogazzi, GB; Locatelli, F; Ponticelli, C; Pozzi, C, 1999) |
| "20-50% of patients with IgA nephropathy (IgAN) reach end-stage renal failure." | 2.69 | Long term treatment of IgA nephropathy with cyclosporine A. ( Chábová, V; Jirsa, M; Merta, M; Rychlik, I; Stejskalová, A; Tesar, V; Zabka, J, 2000) |
| "Twenty children and adolescents with IgA glomerulonephritis were enrolled in a crossover trial." | 2.67 | Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. ( Fryer, C; Quinlan, M; Shely, E; Welch, TR; Witte, DP, 1992) |
| "Idiopathic IgA nephropathy is widely regarded as a slowly progressive disease that not infrequently results in end-stage renal failure." | 2.40 | Plasmapheresis for crescentic IgA nephropathy: a report of two cases and review of the literature. ( Chambers, ME; Hall, FW; McDonald, BR; Rabetoy, GM, 1999) |
| "The condition known as IgA nephropathy was first identified when Berger observed mesangial staining for IgA in healthy patients with isolated hematuria." | 2.40 | Management of IgA nephropathy: evidence-based recommendations. ( Courteau, M; Nolin, L, 1999) |
| "IgA nephropathy was found in 8% of children with isolated proteinuria and has been reported with human immunodeficiency virus infection." | 2.38 | Schönlein-Henoch nephritis and IgA nephropathy in children. ( Gauthier, B, 1993) |
| "In this single center study on immunoglobulin A nephropathy patients with active lesions and major urinary abnormalities and at increased risk of glucocorticosteroid-related complications, a mycophenolate mofetil-based regimen demonstrated similar outcomes in terms of complete response and relapse (at 1 and 5 years) compared to a conventional glucocorticosteroid-based protocol, while achieving a consistent reduction of glucocorticosteroid cumulative dose." | 1.91 | The steroid-sparing effects of a mycophenolate mofetil-based regimen in the management of immunoglobulin A nephropathy in patients with histologically active lesions: A comparison with a control cohort receiving conventional therapy. ( Careddu, A; Fenoglio, R; Ferro, M; Naretto, C; Quattrocchio, G; Roccatello, D; Sciascia, S, 2023) |
| " However, pediatric clinical trials to identify the correct dosage and tolerability of TRF-budesonide are urgently needed." | 1.91 | A pediatric case of IgA nephropathy benefitting from targeted release formulation-budesonide. ( Antonucci, L; Colucci, M; Emma, F; Vivarelli, M, 2023) |
| "The specific treatment regimens of IgA nephropathy (IgAN) patients with moderate proteinuria (1." | 1.62 | Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria. ( Pei, G; Qin, W; Tan, J; Tan, L; Tang, Y; Zhong, Z, 2021) |
| "Crescent formation in immunoglobulin A nephropathy (IgAN) has been demonstrated to be a risk factor for worse outcomes." | 1.56 | Efficacy of corticosteroids in immunoglobulin A nephropathy with less than 25% crescents. ( Chen, J; Li, C; Lin, L; Liu, S; Peng, Z; Xu, H; Zhu, X, 2020) |
| "We describe a 55-year-old male IgA nephropathy patient who was admitted with high fever and hematuria." | 1.56 | A case presentation of an IgA nephropathy patient with Vogt-Koyanagi-Harada syndrome. ( Fan, X; Han, H; Tian, M; Zhang, Q, 2020) |
| "IgA nephropathy is associated with aberrant O-glycosylation of IgA1, which is recognized by autoantibodies leading to the formation of circulating immune complexes." | 1.48 | Glucocorticoids Reduce Aberrant O-Glycosylation of IgA1 in IgA Nephropathy Patients. ( Czernekova, L; Hill, M; Hruby, M; Jemelkova, J; Kafkova, LR; Kosztyu, P; Matousovic, K; Mestecky, J; Raska, M; Sterzl, I; Vondrak, K; Zadrazil, J, 2018) |
| "IgA nephropathy is one of the most common causes of renal hypertension." | 1.48 | Pregnancy-induced complications in IgA nephropathy: A case report. ( Chen, H; Fan, L; Li, X; Tian, G; Wu, Y, 2018) |
| "While IgA nephropathy has been associated with a variety of other diseases, pulmonary complications are extremely rare." | 1.48 | IgA nephropathy with diffuse alveolar haemorrhage. ( Hattori, A; Ikeda, T; Kuno, Y; Miyazaki, S, 2018) |
| "No specific treatment for IgA nephropathy (IgAN) after kidney transplantation is currently available." | 1.43 | Treatment protocol with pulse and oral steroids for IgA Nephropathy after kidney transplantation. ( Ariaudo, C; Biancone, L; di Vico, MC; Fop, F; Mazzucco, G; Messina, M; Segoloni, GP, 2016) |
| " The area under the curves (AUC) of immunosuppressants was calculated by the plot of plasma trough level or dosage of each immunosuppressant versus time and was interpreted as the extent of drug exposure." | 1.43 | Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy. ( Barratt, J; Kim, MJ; Koller, MT; Molyneux, K; Schaub, S; Stampf, S, 2016) |
| "Under a diagnosis of testicular cancer from manipulation test and ultrasonography, high orchiectomy was performed." | 1.42 | [Primary testicular malignant lymphoma in a hemodialysis patient : a case report]. ( Hamao, T; Nakatsuji, H; Sakaki, M, 2015) |
| "The prednisone dose was reduced stepwise during the combined treatment." | 1.42 | Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children. ( Ding, Y; Duan, C; Kang, Z; Li, Z; Wu, T; Xun, M; Yin, Y; Zhang, L; Zhang, Y, 2015) |
| "Patients (n = 84) with severe IgA nephropathy received either MMF/prednisone (MMF group) or CYC/prednisone (CYC group)." | 1.40 | Treatment of severe IgA nephropathy: mycophenolate mofetil/prednisone compared to cyclophosphamide/prednisone. ( Dewei, D; He, L; Liu, H; Liu, X; Sun, S; Xu, G; Zhang, P, 2014) |
| "There were 70 IgA nephropathy patients of whom 46 were men." | 1.37 | Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran. ( Broomand, B; Najafi, I; Salimi, BH; Soleymanian, T, 2011) |
| "Of 850 IgA nephropathy (IgAN) patients that were followed up in our renal centre, 32 received MMF (1-1." | 1.35 | Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. ( Cui, Z; Lv, J; Su, T; Wang, H; Zhang, H; Zhang, Y, 2008) |
| "We describe a case of onset of immunoglobulin A nephropathy (Berger disease) after S aureus septic arthritis complicating an anterior cruciate ligament surgical reconstruction." | 1.32 | Onset of Berger disease after Staphylococcus aureus infection: septic arthritis after anterior cruciate ligament reconstruction. ( Canducci, F; De Santis, V; Delcogliano, A; Gasbarrini, A; Logroscino, G; Pola, E, 2003) |
| "IgA nephropathy is one of the most common causes of glomerulonephritis in the world and is characterized histologically by the deposition of polymeric forms of IgA within the mesangium and in some cases along the glomerular capillary wall." | 1.32 | Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. ( Hennigar, RA; Tumlin, JA, 2004) |
| " Dosage began at 60 mg/m2 for 3 month, was reduced to 30 mg/m2 by 1 year and 15 mg/m2 by 2 years." | 1.29 | Treatment of IgA nephropathy in children: efficacy of alternate-day oral prednisone. ( Benfield, MR; Herrera, GA; Kelly, DR; Kohaut, EC; Waldo, FB; Wyatt, RJ, 1993) |
| "Five patients had chronic renal failure (as disclosed by plasma creatinine of 230 +/- 71 mumol/L), hypertension, and proteinuria (2." | 1.29 | Immunosuppressive treatment of Berger's disease. ( Bartoli, E; Bosincu, L; Faedda, R; Pirisi, M; Satta, A, 1996) |
| "The prevalence of IgA nephropathy (IgAN) varies among racial groups, being most common among Caucasians and Orientals and rare in Blacks." | 1.28 | IgA nephropathy in blacks: studies of IgA2 allotypes and clinical course. ( Crowley-Nowick, PA; Galla, JH; Jackson, S; Julian, BA; Mestecky, J; Wall, BM; Warnock, DG; Wyatt, RJ, 1991) |
| "We treated ten children with severe IgA nephropathy (IgAN) [proteinuria greater than 1 g/day, hypertension, renal insufficiency, segmental sclerosis, crescent formation and/or glomerular basement membrane (GBM) deposition of IgA] with prednisone and azathioprine for 1 year." | 1.28 | Treatment of severe IgA nephropathy in children. ( Andreoli, SP; Bergstein, JM, 1989) |
| "It was difficult for WM in treating IgA nephropathy, membrano-proliferative GN and focal glomerulosclerosis, but Chinese medicinal herbs were effective with replenishing Qi and strengthening the Spleen, clearing away Dampness-Heat, promoting blood circulation and relieving Stasis, etc." | 1.28 | [Analysis of the treatment with traditional Chinese medicine in chronic glomerulonephritis based on histopathologic type]. ( Chen, YP; Hu, ZY; Zha, P, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (12.09) | 18.7374 |
| 1990's | 18 (19.78) | 18.2507 |
| 2000's | 22 (24.18) | 29.6817 |
| 2010's | 28 (30.77) | 24.3611 |
| 2020's | 12 (13.19) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 1 |
| Fu, R | 2 |
| Gao, J | 1 |
| Wang, L | 1 |
| Duan, Z | 1 |
| Tian, L | 1 |
| Ge, H | 1 |
| Ma, X | 2 |
| Zhang, Y | 5 |
| Li, K | 1 |
| Xu, P | 1 |
| Tian, X | 1 |
| Chen, Z | 1 |
| Liang, M | 1 |
| Xiong, L | 1 |
| Li, A | 1 |
| Zhou, J | 1 |
| Huang, Y | 1 |
| Huang, M | 1 |
| Zhang, X | 1 |
| Shi, H | 1 |
| Su, N | 1 |
| Wei, Y | 1 |
| Jiang, Z | 1 |
| Antonucci, L | 1 |
| Colucci, M | 1 |
| Emma, F | 1 |
| Vivarelli, M | 1 |
| Roccatello, D | 4 |
| Careddu, A | 1 |
| Ferro, M | 4 |
| Naretto, C | 1 |
| Quattrocchio, G | 3 |
| Fenoglio, R | 1 |
| Sciascia, S | 1 |
| Takhar, JS | 1 |
| Gonzales, JA | 1 |
| Chen, J | 2 |
| Xu, H | 1 |
| Peng, Z | 1 |
| Lin, L | 1 |
| Li, C | 1 |
| Zhu, X | 1 |
| Liu, S | 1 |
| Wang, X | 1 |
| Li, T | 2 |
| Si, R | 1 |
| Qu, Z | 1 |
| Jiang, Y | 1 |
| Zhang, Q | 2 |
| Fan, X | 1 |
| Tian, M | 1 |
| Han, H | 1 |
| Zhong, Z | 1 |
| Tang, Y | 2 |
| Tan, J | 1 |
| Tan, L | 1 |
| Pei, G | 1 |
| Qin, W | 1 |
| Rubin, J | 1 |
| Sclafani, A | 1 |
| Helland, TL | 1 |
| Sharma, A | 1 |
| Maley, JH | 1 |
| Peck, TJ | 1 |
| Wallwork, RS | 1 |
| Bolster, MB | 1 |
| Berigei, S | 1 |
| Colson, YL | 1 |
| Selig, MK | 1 |
| Mino-Kenudson, M | 1 |
| Hariri, LP | 1 |
| Peng, XJ | 1 |
| Zheng, WM | 1 |
| Huang, YH | 1 |
| Deng, MH | 1 |
| Tao, SS | 1 |
| Wang, TJ | 1 |
| Zhu, C | 1 |
| Ni, Z | 1 |
| Zhang, Z | 1 |
| Yu, Z | 1 |
| Lu, F | 1 |
| Mei, C | 1 |
| Ding, X | 1 |
| Yuan, W | 1 |
| Zhang, W | 1 |
| Jiang, G | 1 |
| Sun, M | 1 |
| He, L | 2 |
| Deng, Y | 1 |
| Pang, H | 1 |
| Qian, J | 1 |
| Windon, AL | 1 |
| Shroff, SG | 1 |
| Kosztyu, P | 1 |
| Hill, M | 1 |
| Jemelkova, J | 1 |
| Czernekova, L | 1 |
| Kafkova, LR | 1 |
| Hruby, M | 1 |
| Matousovic, K | 1 |
| Vondrak, K | 1 |
| Zadrazil, J | 1 |
| Sterzl, I | 1 |
| Mestecky, J | 2 |
| Raska, M | 1 |
| Chen, H | 1 |
| Li, X | 1 |
| Wu, Y | 1 |
| Fan, L | 1 |
| Tian, G | 1 |
| Lin, Y | 1 |
| Jia, J | 1 |
| Guo, Y | 1 |
| He, D | 1 |
| Wang, F | 1 |
| Yan, T | 1 |
| Liu, Y | 1 |
| Lin, S | 1 |
| Simeoni, M | 1 |
| Nicotera, R | 1 |
| Pelagi, E | 1 |
| Libri, E | 1 |
| Comi, N | 1 |
| Fuiano, G | 1 |
| Miyazaki, S | 1 |
| Hattori, A | 1 |
| Kuno, Y | 1 |
| Ikeda, T | 1 |
| Cheung, CY | 1 |
| Chak, WL | 1 |
| Yang, YZ | 1 |
| Chen, P | 1 |
| Liu, LJ | 2 |
| Cai, QQ | 1 |
| Shi, SF | 2 |
| Chen, YQ | 2 |
| Lv, JC | 2 |
| Zhang, H | 5 |
| Wang, J | 1 |
| Juan, C | 1 |
| Huang, Q | 1 |
| Zeng, C | 1 |
| Liu, Z | 1 |
| Liu, X | 1 |
| Dewei, D | 1 |
| Sun, S | 1 |
| Xu, G | 1 |
| Liu, H | 1 |
| Zhang, P | 1 |
| Krisl, JC | 1 |
| Alloway, RR | 1 |
| Shields, AR | 1 |
| Cardi, MA | 1 |
| Woodle, ES | 1 |
| Xu, L | 1 |
| Liu, ZC | 1 |
| Guan, GJ | 1 |
| Lv, XA | 1 |
| Luo, Q | 1 |
| Löffler, C | 1 |
| Löffler, U | 1 |
| Tuleweit, A | 1 |
| Waldherr, R | 1 |
| Uppenkamp, M | 1 |
| Bergner, R | 1 |
| Wan, QJ | 1 |
| Hu, HF | 1 |
| He, YC | 1 |
| Luan, SD | 1 |
| Chen, HT | 1 |
| Liu, HP | 1 |
| Xu, Y | 1 |
| Xu, HL | 1 |
| Liao, Y | 1 |
| Kang, Z | 1 |
| Li, Z | 1 |
| Duan, C | 1 |
| Wu, T | 1 |
| Xun, M | 1 |
| Ding, Y | 1 |
| Zhang, L | 1 |
| Yin, Y | 1 |
| Nakatsuji, H | 1 |
| Sakaki, M | 1 |
| Hamao, T | 1 |
| Chen, F | 1 |
| Ma, YL | 1 |
| Ding, H | 1 |
| Chen, BP | 1 |
| Messina, M | 1 |
| di Vico, MC | 1 |
| Ariaudo, C | 1 |
| Mazzucco, G | 2 |
| Fop, F | 1 |
| Segoloni, GP | 1 |
| Biancone, L | 1 |
| Kim, MJ | 1 |
| Schaub, S | 1 |
| Molyneux, K | 1 |
| Koller, MT | 1 |
| Stampf, S | 1 |
| Barratt, J | 1 |
| Hou, JH | 1 |
| Le, WB | 1 |
| Chen, N | 1 |
| Wang, WM | 1 |
| Liu, ZS | 1 |
| Liu, D | 1 |
| Chen, JH | 1 |
| Tian, J | 1 |
| Fu, P | 1 |
| Hu, ZX | 1 |
| Zeng, CH | 1 |
| Liang, SS | 1 |
| Zhou, ML | 1 |
| Zhang, HT | 1 |
| Liu, ZH | 1 |
| Lv, J | 3 |
| Chen, Y | 1 |
| Li, G | 1 |
| Jiang, L | 1 |
| Singh, AK | 1 |
| Wang, H | 4 |
| Strippoli, GF | 1 |
| Maione, A | 1 |
| Schena, FP | 2 |
| Tognoni, G | 1 |
| Craig, JC | 1 |
| Aires, I | 1 |
| Carvalho, D | 1 |
| Remédio, F | 1 |
| Possante, M | 1 |
| Ferreira, A | 1 |
| Pinto, JR | 1 |
| Nolasco, F | 1 |
| Santos, JR | 1 |
| Manno, C | 1 |
| Torres, DD | 1 |
| Rossini, M | 1 |
| Pesce, F | 1 |
| Shen, PC | 1 |
| He, LQ | 1 |
| Wang, Q | 1 |
| Wang, W | 1 |
| Li, J | 1 |
| Eitner, F | 1 |
| Floege, J | 1 |
| Liu, XW | 1 |
| Li, DM | 1 |
| Xu, GS | 1 |
| Sun, SR | 1 |
| Hirayama, M | 1 |
| Yuzawa, M | 1 |
| Takada, M | 1 |
| Hirayama, K | 1 |
| Lujan, BJ | 1 |
| Sadda, SR | 1 |
| Keane, PA | 1 |
| Heras, M | 1 |
| Saiz, A | 1 |
| Pardo, J | 1 |
| Fernández-Reyes, MJ | 1 |
| Sánchez, R | 1 |
| Alvarez-Ude, F | 1 |
| Soleymanian, T | 1 |
| Najafi, I | 1 |
| Salimi, BH | 1 |
| Broomand, B | 1 |
| Zhu, L | 1 |
| Wang, HY | 1 |
| Xu, D | 1 |
| Perkovic, V | 1 |
| Johnson, DW | 1 |
| Woodward, M | 1 |
| Levin, A | 1 |
| Pola, E | 1 |
| Logroscino, G | 1 |
| De Santis, V | 1 |
| Canducci, F | 1 |
| Delcogliano, A | 1 |
| Gasbarrini, A | 1 |
| Tang, X | 1 |
| Yagi, K | 1 |
| Okada, M | 1 |
| Yanagida, H | 1 |
| Kuwajima, H | 1 |
| Ikeda, M | 1 |
| Sugimoto, K | 1 |
| Takemura, T | 1 |
| Tumlin, JA | 1 |
| Hennigar, RA | 1 |
| García Camín, RM | 1 |
| Cabezas, A | 1 |
| Calero, F | 1 |
| Ballarín, JA | 1 |
| Tibbs, ME | 1 |
| Andreoli, SP | 2 |
| Phillips, CL | 1 |
| Lau, KK | 1 |
| Delos Santos, NM | 1 |
| Fernandes, PF | 1 |
| Júnior, GB | 1 |
| Barros, FA | 1 |
| Sousa, DC | 1 |
| Franco, LM | 1 |
| Patrocínio, RM | 1 |
| Hogg, RJ | 2 |
| Lee, J | 1 |
| Nardelli, N | 1 |
| Julian, BA | 3 |
| Cattran, D | 1 |
| Waldo, B | 1 |
| Wyatt, R | 1 |
| Jennette, JC | 1 |
| Sibley, R | 1 |
| Hyland, K | 1 |
| Fitzgibbons, L | 1 |
| Hirschman, G | 1 |
| Donadio, JV | 1 |
| Holub, BJ | 1 |
| Cui, Z | 1 |
| Su, T | 1 |
| Goumenos, D | 1 |
| Ahuja, M | 1 |
| Shortland, JR | 1 |
| Brown, CB | 1 |
| Coppo, R | 2 |
| Piccoli, G | 3 |
| Ferrario, F | 2 |
| Napodano, P | 2 |
| Rastaldi, MP | 2 |
| D'Amico, G | 2 |
| Alon, US | 1 |
| Waldo, FB | 2 |
| Wyatt, RJ | 3 |
| Kelly, DR | 1 |
| Herrera, GA | 1 |
| Benfield, MR | 1 |
| Kohaut, EC | 2 |
| Barker, C | 1 |
| Gauthier, B | 1 |
| Giraudo, G | 1 |
| Faedda, R | 1 |
| Pirisi, M | 1 |
| Satta, A | 1 |
| Bosincu, L | 1 |
| Bartoli, E | 1 |
| Wei, L | 1 |
| Pozzi, C | 1 |
| Bolasco, PG | 1 |
| Fogazzi, GB | 1 |
| Andrulli, S | 1 |
| Altieri, P | 1 |
| Ponticelli, C | 1 |
| Locatelli, F | 1 |
| Nolin, L | 1 |
| Courteau, M | 1 |
| Chambers, ME | 1 |
| McDonald, BR | 1 |
| Hall, FW | 1 |
| Rabetoy, GM | 1 |
| Blanco Sampascual, S | 1 |
| de las Heras Niño, B | 1 |
| Marcé Landeta, L | 1 |
| Orive Cura, V | 1 |
| Chábová, V | 1 |
| Tesar, V | 1 |
| Zabka, J | 1 |
| Rychlik, I | 1 |
| Merta, M | 1 |
| Jirsa, M | 1 |
| Stejskalová, A | 1 |
| Cesano, G | 1 |
| Rossi, D | 1 |
| Berutti, S | 1 |
| Salomone, M | 1 |
| Sena, LM | 1 |
| Arrigo, G | 1 |
| Matsumoto, K | 1 |
| Kanmatsuse, K | 1 |
| Szymanik-Grzelak, H | 1 |
| Mizerska-Wasiak, M | 1 |
| Roszkowska-Blaim, M | 1 |
| Tomiyoshi, Y | 1 |
| Sakemi, T | 1 |
| Ikeda, Y | 1 |
| Ohtsuka, Y | 1 |
| Nakamura, M | 1 |
| Fujisaki, T | 1 |
| Bo, S | 1 |
| Ju, J | 1 |
| Chu, D | 1 |
| Rodríguez García, A | 1 |
| Gallego, E | 1 |
| Navarro, JF | 1 |
| Hu, ZY | 1 |
| Chen, YP | 2 |
| Zha, P | 1 |
| Welch, TR | 2 |
| Fryer, C | 1 |
| Shely, E | 1 |
| Witte, DP | 1 |
| Quinlan, M | 1 |
| Crowley-Nowick, PA | 1 |
| Galla, JH | 1 |
| Wall, BM | 1 |
| Warnock, DG | 1 |
| Jackson, S | 1 |
| Bergstein, JM | 1 |
| Korzets, A | 1 |
| Gafter, U | 1 |
| Zevin, D | 1 |
| Levi, J | 1 |
| Cheng, IK | 1 |
| Chan, KW | 2 |
| Chan, MK | 1 |
| Alexander, R | 1 |
| Smolin, MR | 1 |
| Rickman, W | 1 |
| Hasbargen, J | 1 |
| McAdams, AJ | 2 |
| Berry, A | 1 |
| Lai, KN | 1 |
| Lai, FM | 1 |
| Ho, CP | 1 |
| Kühn, K | 1 |
| Brodehl, J | 1 |
| Koch, KM | 1 |
| Helmchen, U | 1 |
| Sinnassamy, P | 1 |
| O'Regan, S | 1 |
| McEnery, PT | 1 |
| West, CD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial.[NCT02160132] | Phase 2 | 180 participants (Anticipated) | Interventional | 2014-06-30 | Recruiting | ||
| Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)[NCT04937907] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-09-08 | Recruiting | ||
| The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy[NCT01451710] | 30 participants (Actual) | Interventional | 2011-03-31 | Completed | |||
| [NCT00378443] | 0 participants | Interventional | 2006-01-31 | Active, not recruiting | |||
| Effect of Immunosuppression in IgA Nephropathy[NCT03468972] | Phase 4 | 174 participants (Anticipated) | Interventional | 2019-03-31 | Not yet recruiting | ||
| Randomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis of IgA NEphropathy (RESCUE Study)[NCT02647255] | Phase 2/Phase 3 | 10 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to Due to the rarity and rapid progressive course of the disease, patients were less likely to participate in randomization.) | ||
| Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Crescents : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial.[NCT04833374] | Phase 3 | 200 participants (Anticipated) | Interventional | 2021-05-24 | Recruiting | ||
| Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy[NCT00367562] | Phase 4 | 20 participants | Interventional | 1996-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for prednisone and Berger Disease
| Article | Year |
|---|---|
Efficacy and safety of mycophenolate mofetil in the treatment for IgA nephropathy: a meta-analysis of randomized controlled trials.
Topics: Antibiotics, Antineoplastic; Drug Therapy, Combination; Glomerulonephritis, IGA; Glucocorticoids; Hu | 2021 |
Iatrogenic Kaposi's Sarcoma in an HIV-Negative Young Male With Crohn's Disease and IgA Nephropathy: A Case Report and Brief Review of the Literature.
Topics: Anti-Inflammatory Agents; Crohn Disease; Glomerulonephritis, IGA; Humans; Iatrogenic Disease; Immuno | 2018 |
Corticosteroid for IgA Nephropathy: Are They Really Therapeutic?
Topics: Glomerulonephritis, IGA; Glucocorticoids; Humans; Prednisone; Randomized Controlled Trials as Topic; | 2018 |
Corticosteroid therapy in IgA nephropathy.
Topics: Administration, Oral; Adrenal Cortex Hormones; China; Disease-Free Survival; Dose-Response Relations | 2012 |
Schönlein-Henoch nephritis and IgA nephropathy in children.
Topics: Child; Glomerulonephritis, IGA; Humans; Nephritis; Prednisone; Prognosis | 1993 |
[Advances in the research on immunoglobulin A nephropathy].
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Glomerulonephritis, IGA; Glucocorticoids; | 1996 |
Management of IgA nephropathy: evidence-based recommendations.
Topics: Adult; Anti-Inflammatory Agents; Evidence-Based Medicine; Glomerulonephritis, IGA; Humans; Practice | 1999 |
Plasmapheresis for crescentic IgA nephropathy: a report of two cases and review of the literature.
Topics: Adolescent; Adult; Combined Modality Therapy; Cyclophosphamide; Glomerulonephritis, IGA; Humans; Imm | 1999 |
23 trials available for prednisone and Berger Disease
| Article | Year |
|---|---|
Effect of pulsed intravenous methylprednisolone with alternative low-dose prednisone on high-risk IgA nephropathy: a 18-month prospective clinical trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Disease Progression; Drug Tapering; Drug T | 2022 |
The effectiveness and safety of corticosteroid therapy for IgA nephropathy with crescents: a prospective, randomized, controlled study.
Topics: Adult; Female; Glomerulonephritis, IGA; Glucocorticoids; Humans; Infusions, Intravenous; Male; Methy | 2022 |
Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial.
Topics: Adult; China; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulone | 2021 |
Corticosteroid therapy in IgA nephropathy with minimal change-like lesions: a single-centre cohort study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Biomarkers; Female; Follow-Up Studies; Glomerular Filtr | 2013 |
Cyclosporine A combined with medium/low dose prednisone in progressive IgA nephropathy.
Topics: Adult; Biomarkers; Cyclosporine; Disease Progression; Drug Therapy, Combination; Female; Glomerulone | 2014 |
Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.
Topics: Adult; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulonephritis, IGA; Gluco | 2017 |
Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Topics: Adrenal Cortex Hormones; Adult; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Cilazapril; Creati | 2009 |
Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Topics: Adrenal Cortex Hormones; Adult; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Cilazapril; Creati | 2009 |
Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Topics: Adrenal Cortex Hormones; Adult; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Cilazapril; Creati | 2009 |
Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Topics: Adrenal Cortex Hormones; Adult; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Cilazapril; Creati | 2009 |
Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
Topics: Adrenal Cortex Hormones; Adult; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; | 2009 |
Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Drug Therapy, Combination; Female; Glomerulonephritis, | 2010 |
[Effect of ligustrazine on proliferative glomerulonephritis].
Topics: Adolescent; Adult; Creatinine; Cyclophosphamide; Dipyridamole; Drug Therapy, Combination; Female; Fi | 2003 |
Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy.
Topics: Adolescent; Adult; Age of Onset; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; | 2003 |
Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group.
Topics: Adult; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fatty Acids, Om | 2006 |
A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with immunoglobulin A nephropathy. Scientific Planning Committee of the IgA Nephropathy Study.
Topics: Adolescent; Adult; Child; Drug Administration Schedule; Enalapril; Fish Oils; Glomerulonephritis, IG | 1995 |
Treatment of rapidly progressive IgA nephropathy.
Topics: Antibodies, Antineutrophil Cytoplasmic; Arteritis; Autoantibodies; Biopsy; Combined Modality Therapy | 1995 |
Alternate-day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomized, controlled trial.
Topics: Adolescent; Adult; Creatinine; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glom | 1993 |
Corticosteroids in IgA nephropathy: a randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo | 1999 |
Corticosteroids in IgA nephropathy: a randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo | 1999 |
Corticosteroids in IgA nephropathy: a randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo | 1999 |
Corticosteroids in IgA nephropathy: a randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo | 1999 |
Corticosteroids in IgA nephropathy: a randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo | 1999 |
Corticosteroids in IgA nephropathy: a randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo | 1999 |
Corticosteroids in IgA nephropathy: a randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo | 1999 |
Corticosteroids in IgA nephropathy: a randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo | 1999 |
Corticosteroids in IgA nephropathy: a randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo | 1999 |
Long term treatment of IgA nephropathy with cyclosporine A.
Topics: Adult; Cyclosporine; Female; Glomerulonephritis, IGA; Glucocorticoids; Humans; Male; Prednisone; Pro | 2000 |
Steroid and cyclophosphamide in IgA nephropathy.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Female; Glomerulonephritis, IG | 2000 |
[Evaluation of prednisone treatment in children with IgA nephropathy and Schönlein-Henoch nephropathy according to the Waldo protocol with regard to pathomorphologic changes in renal biopsy].
Topics: Adolescent; Anti-Inflammatory Agents; Biopsy; Child; Child, Preschool; Drug Administration Schedule; | 2001 |
[Clinical study on Shenning Mixture in treating IgA nephropathy].
Topics: Adolescent; Adult; Drugs, Chinese Herbal; Female; Glomerulonephritis, IGA; Glucocorticoids; Humans; | 2000 |
Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis.
Topics: Adolescent; Child; Creatinine; Double-Blind Method; Female; Glomerulonephritis, IGA; Hematuria; Huma | 1992 |
Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Clinical Trials as Topic; Female; Glomerulonep | 1986 |
[Drug treatment of chronic glomerulonephritis: pro].
Topics: Chlorambucil; Chronic Disease; Clinical Trials as Topic; Cyclophosphamide; Cyclosporins; Glomerulone | 1985 |
60 other studies available for prednisone and Berger Disease
| Article | Year |
|---|---|
A pediatric case of IgA nephropathy benefitting from targeted release formulation-budesonide.
Topics: Adolescent; Adult; Budesonide; Child; Glomerulonephritis, IGA; Hematuria; Humans; Male; Prednisone; | 2023 |
The steroid-sparing effects of a mycophenolate mofetil-based regimen in the management of immunoglobulin A nephropathy in patients with histologically active lesions: A comparison with a control cohort receiving conventional therapy.
Topics: Drug Therapy, Combination; Glomerulonephritis, IGA; Hematuria; Humans; Immunosuppressive Agents; Met | 2023 |
IgA Nephropathy-Associated Uveitis: A Case Presentation.
Topics: Administration, Oral; Adult; Female; Fluorescein Angiography; Glomerulonephritis, IGA; Glucocorticoi | 2020 |
Efficacy of corticosteroids in immunoglobulin A nephropathy with less than 25% crescents.
Topics: Adrenal Cortex Hormones; Adult; China; Disease Progression; Female; Glomerular Filtration Rate; Glom | 2020 |
Increased frequency of PD-1
Topics: Adolescent; Adult; Aged; B-Lymphocytes; Benzazepines; Case-Control Studies; Female; Glomerulonephrit | 2020 |
A case presentation of an IgA nephropathy patient with Vogt-Koyanagi-Harada syndrome.
Topics: Cyclophosphamide; Fluorescein Angiography; Glomerulonephritis, IGA; Glucocorticoids; Humans; Immunos | 2020 |
Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria.
Topics: Adrenal Cortex Hormones; Adult; Drug Therapy, Combination; Female; Glomerulonephritis, IGA; Humans; | 2021 |
Pulmonary Hemosiderosis with Calcification Associated with IgA Nephropathy.
Topics: Calcinosis; Glomerulonephritis, IGA; Glucocorticoids; Hemosiderosis; Hispanic or Latino; Humans; Lun | 2021 |
Glucocorticoids Reduce Aberrant O-Glycosylation of IgA1 in IgA Nephropathy Patients.
Topics: Antibodies; Antigen-Antibody Complex; Case-Control Studies; Glomerulonephritis, IGA; Glucocorticoids | 2018 |
Pregnancy-induced complications in IgA nephropathy: A case report.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Benzoates; Biopsy; Blood Pressure; Cyclophosphamide; | 2018 |
Successful Use of Aliskiren in a Case of IgA- Mesangial Glomerulonephritis Unresponsive to Conventional Therapies.
Topics: Amides; Biopsy, Needle; Drug Administration Schedule; Drug Resistance, Multiple; Drug Therapy, Combi | 2019 |
IgA nephropathy with diffuse alveolar haemorrhage.
Topics: Biopsy; Glomerulonephritis, IGA; Hemorrhage; Humans; Kidney; Lung Diseases; Male; Middle Aged; Predn | 2018 |
A rare diagnosis of primary native kidney non-hodgkin's lymphoma after kidney transplantation.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone N | 2019 |
Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study.
Topics: Adrenal Cortex Hormones; Adult; Case-Control Studies; Female; Glomerular Filtration Rate; Glomerulon | 2019 |
Treatment of severe IgA nephropathy: mycophenolate mofetil/prednisone compared to cyclophosphamide/prednisone.
Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Female; Glomerulonephritis, IGA; Humans; Immunos | 2014 |
Bortezomib-based antibody-mediated rejection therapy and simultaneous conversion to belatacept.
Topics: Abatacept; Adult; Azathioprine; Biopsy; Boronic Acids; Bortezomib; Calcineurin Inhibitors; Cyclospor | 2014 |
Renal sarcoidosis: epidemiological and follow-up data in a cohort of 27 patients.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Female; Follow-Up Studies; Germany; Glomerular Filtration Ra | 2015 |
Severe pneumonia in mycophenolate mofetil combined with low-dose corticosteroids-treated patients with immunoglobulin A nephropathy.
Topics: Adrenal Cortex Hormones; Adult; Female; Glomerulonephritis, IGA; Humans; Immunoglobulin A; Male; Met | 2015 |
Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Child; Child, Preschool; D | 2015 |
[Primary testicular malignant lymphoma in a hemodialysis patient : a case report].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemor | 2015 |
Effects of Tripterygium wilfordii glycosides on regulatory T cells and Th17 in an IgA nephropathy rat model.
Topics: Animals; Disease Models, Animal; Glomerulonephritis, IGA; Glycosides; Humans; Prednisone; Rats; T-Ly | 2015 |
Treatment protocol with pulse and oral steroids for IgA Nephropathy after kidney transplantation.
Topics: Administration, Intravenous; Administration, Oral; Adult; Clinical Protocols; Creatinine; Female; Fo | 2016 |
Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy.
Topics: Antibodies, Monoclonal; Basiliximab; Drug Therapy, Combination; Female; Galactose; Glomerulonephriti | 2016 |
IgA nephropathy: a disease in search of a large-scale clinical trial to reliably inform practice.
Topics: Adrenal Cortex Hormones; Angiotensin-Converting Enzyme Inhibitors; Cilazapril; Creatinine; Drug Ther | 2009 |
Sirolimus-induced drug fever in a renal transplant patient: a case report.
Topics: Fever; Glomerulonephritis, IGA; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Tr | 2009 |
Clinicopathological characteristics and prognostic factors of asymptomatic IgA nephropathy.
Topics: Adult; Biopsy; Female; Follow-Up Studies; Glomerulonephritis, IGA; Humans; Male; Prednisone; Prognos | 2010 |
Glomerular disease: ACEIs with or without corticosteroids in IgA nephropathy?
Topics: Adrenal Cortex Hormones; Angiotensin-Converting Enzyme Inhibitors; Disease Progression; Drug Therapy | 2010 |
Diagnostic and therapeutic challenges.
Topics: Aged; Central Serous Chorioretinopathy; Chronic Disease; Fluorescein Angiography; Glomerulonephritis | 2011 |
[Rapidly progressive renal failure as the onset of an IgA nephropathy in an elderly patient].
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Biphenyl Compounds; Disease Progression; Diuretics; Doxaz | 2011 |
Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2011 |
Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy.
Topics: Actins; Adolescent; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitor | 2012 |
Onset of Berger disease after Staphylococcus aureus infection: septic arthritis after anterior cruciate ligament reconstruction.
Topics: Adult; Anterior Cruciate Ligament; Anti-Infective Agents; Anti-Inflammatory Agents; Arthritis, Infec | 2003 |
Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Chi-Square Distribution; Cyclophosphamide; Disease Progres | 2004 |
[Steroid-responsive nephrotic syndrome in IgA nephropathy].
Topics: Biopsy; Cyclophosphamide; Cyclosporine; Diabetes Mellitus; Drug Therapy, Combination; Glomerulonephr | 2004 |
Membranoproliferative glomerulonephritis type II in a 10-year-old girl.
Topics: Child; Clinical Chemistry Tests; Diagnosis, Differential; Drug Therapy, Combination; Enalapril; Fema | 2005 |
Post-infectious acute glomerulonephritis with predominant mesangial deposition of IgA.
Topics: Child; Glomerular Mesangium; Glomerulonephritis, IGA; Humans; Male; Prednisone; Quinapril; Tetrahydr | 2005 |
Behcet's disease and IgA nephropathy: report of this association in a patient from Brazil and literature review.
Topics: Adult; Anti-Inflammatory Agents; Behcet Syndrome; Biopsy; Brazil; Cyclophosphamide; Drug Therapy, Co | 2006 |
Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy.
Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulonep | 2008 |
Can immunosuppressive drugs slow the progression of IgA nephropathy?
Topics: Adolescent; Adult; Aged; Azathioprine; Biopsy; Disease Progression; Female; Glomerulonephritis, IGA; | 1995 |
Capillaritis in IgA nephropathy.
Topics: Biopsy; Capillaries; Cyclophosphamide; Drug Therapy, Combination; Glomerulonephritis, IGA; Humans; H | 1995 |
Treatment of IgA nephropathy in children.
Topics: Administration, Oral; Child; Glomerulonephritis, IGA; Humans; Prednisone; Proteinuria | 1994 |
Treatment of IgA nephropathy in children: efficacy of alternate-day oral prednisone.
Topics: Administration, Oral; Adolescent; Child; Drug Administration Schedule; Female; Follow-Up Studies; Gl | 1993 |
Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy.
Topics: Adolescent; Adult; Biopsy; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Female; | 1995 |
Immunosuppressive treatment of Berger's disease.
Topics: Adolescent; Adult; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Female | 1996 |
[IgA nephropathy and intrahepatic percutaneous portosystemic shunt].
Topics: Anti-Inflammatory Agents; Follow-Up Studies; Glomerulonephritis, IGA; Humans; Kidney Transplantation | 1999 |
Idiopathic IgA nephropathy with segmental necrotizing lesions of the capillary wall.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Capillaries; Cyclophosphamide; Disease Prog | 2001 |
Transforming growth factor-beta1 inhibits vascular permeability factor release by T cells in normal subjects and in patients with minimal-change nephrotic syndrome.
Topics: Adult; Capillary Permeability; Case-Control Studies; Concanavalin A; Dose-Response Relationship, Dru | 2001 |
Cellular crescents and segmental glomerular necrosis in IgA nephropathy are indicative of the beneficial effects of corticosteroid therapy.
Topics: Adult; Anti-Inflammatory Agents; Creatinine; Female; Glomerulonephritis, IGA; Glucocorticoids; Human | 2001 |
[Macroscopic hematuria after immunization with tetanus toxoid in a patient with IgA nephropathy].
Topics: Adult; Antibodies, Bacterial; Disease Susceptibility; Erythema; Fever; Glomerulonephritis, IGA; Hema | 2002 |
[Analysis of the treatment with traditional Chinese medicine in chronic glomerulonephritis based on histopathologic type].
Topics: Adolescent; Adult; Biopsy, Needle; Child; Chronic Disease; Drugs, Chinese Herbal; Female; Glomerulon | 1992 |
IgA nephropathy in blacks: studies of IgA2 allotypes and clinical course.
Topics: Adult; Black People; Female; Glomerulonephritis, IGA; Hematuria; Humans; Immunoglobulin A; Immunoglo | 1991 |
Treatment of severe IgA nephropathy in children.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Female; Fluorescent Antibody Technique; Follow-Up | 1989 |
Steroid-dependent nephrotic syndrome in IgA nephropathy.
Topics: Glomerulonephritis, IGA; Humans; Male; Middle Aged; Nephrotic Syndrome; Prednisone; Remission Induct | 1989 |
Mesangial IgA nephropathy with steroid-responsive nephrotic syndrome: disappearance of mesangial IgA deposits following steroid-induced remission.
Topics: Adult; Biopsy; Female; Glomerular Mesangium; Glomerulonephritis, IGA; Humans; Immunoglobulin A; Kidn | 1989 |
Alternate-day prednisone therapy in children with IgA-associated nephritis.
Topics: Adolescent; Biopsy; Child; Child, Preschool; Creatinine; Female; Follow-Up Studies; Glomerular Filtr | 1989 |
Hypogammaglobulinemia in a renal transplant recipient with antiglomerular basement membrane disease.
Topics: Adult; Agammaglobulinemia; Anti-Glomerular Basement Membrane Disease; Azathioprine; Basement Membran | 1988 |
Rapidly progressive IgA nephropathy.
Topics: Adolescent; Child; Complement C3; Complement C4; Dipyridamole; Female; Glomerulonephritis, IGA; Huma | 1988 |
[IgA nephropathy with massive proteinuria: response to corticosteroid therapy].
Topics: Adolescent; Adult; Female; Glomerulonephritis, IGA; Humans; Male; Prednisone; Prognosis; Proteinuria | 1986 |
Mesangial IgA deposits with steroid responsive nephrotic syndrome: probable minimal lesion nephrosis.
Topics: Biopsy; Child; Child, Preschool; Diagnosis, Differential; Glomerular Mesangium; Glomerulonephritis, | 1985 |
Glomerular morphology, natural history and treatment of children with IgA-IgG mesangial nephropathy.
Topics: Adolescent; Child; Child, Preschool; Diagnosis, Differential; Female; Fluorescent Antibody Technique | 1973 |